Total Voting Rights

Source: RNS
RNS Number : 6290Y
Belluscura PLC
31 July 2024
 

31 July 2024

 

Belluscura plc

("Belluscura" or the "Company")

 

Total Voting Rights

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the total number of Ordinary Shares in the capital of the Company in issue is 168,408,232 with each Ordinary Share carrying the right to one vote.  There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the Company is 168,408,232.  The above figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

Enquiries:

For further information, please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP

Simon Neicheril, Chief Financial Officer

 

 

 

SPARK Advisory Partners Limited
(NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

 

 

 

Dowgate Capital Limited
(Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Russell Cook /
Nicholas Chambers

 

 

 

MHP Communications
(Financial PR and Investor Relations)

Tel: +44 (0)20 3128 8100 / +44 7884 494112
Email: belluscura@mhpgroup.com

Katie Hunt / Matthew Taylor

 

 

 

 

 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRSDSFEFELSEFW